Comparative Pharmacology
Head-to-head clinical analysis: LEVORPHANOL TARTRATE versus PALLADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVORPHANOL TARTRATE versus PALLADONE.
LEVORPHANOL TARTRATE vs PALLADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levorphanol is a potent opioid analgesic that acts as a mu-opioid receptor agonist. It also has NMDA receptor antagonist activity, inhibits norepinephrine and serotonin reuptake, and acts as a sigma receptor agonist, contributing to its analgesic effects and reduced tolerance development.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
2 mg orally every 6-8 hours as needed for pain; for opioid-tolerant patients, doses up to 4 mg orally every 6-8 hours may be used. Parenterally: 1-2 mg subcutaneously or intramuscularly every 6-8 hours; may be given intravenously at 0.5-1 mg every 6-8 hours.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
None Documented
None Documented
11-16 hours; extended in hepatic impairment (up to 30 hours).
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Renal: approximately 30% as unchanged drug and 50% as glucuronide conjugates; fecal: 20% via biliary excretion.
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Category C
Category C
Opioid Analgesic
Opioid Analgesic